Product Description: Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL)[1][2].
Applications: COVID-19-immunoregulation
Formula: C17H24N8O3
References: [1]Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357./[2]Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534.
CAS Number: 1417318-27-4
Molecular Weight: 388.42
Compound Purity: 99.20
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: TNF Receptor